Cablivi Generic Name & Formulations
Legal Class
General Description
Pharmacological Class
How Supplied
Manufacturer
Generic Availability
Cablivi Indications
Indications
Cablivi Dosage and Administration
Adult
Children
Hepatic Impairment
No formal studies with caplacizumab-yhdp have been conducted in patients with severe acute or chronic hepatic impairment and no data regarding the use of caplacizumab-yhdp in these populations are available. Due to a potential increased risk of bleeding, use of caplacizumab-yhdp in patients with severe hepatic impairment requires close monitoring for bleeding.
Cablivi Contraindications
Not Applicable
Cablivi Boxed Warnings
Not Applicable
Cablivi Warnings/Precautions
Warnings/Precautions
Cablivi Pharmacokinetics
Absorption
The bioavailability of subcutaneous caplacizumab-yhdp is approximately 90%. The maximum concentration was observed 6 to 7 hours after subcutaneous dosing of 10 mg caplacizumab-yhdp once daily in healthy subjects.
Distribution
Caplacizumab-yhdp central volume of distribution is 6.33 L in patients with aTTP.
Elimination
The available nonclinical data suggest unbound caplacizumab-yhdp is cleared renally.
Cablivi Interactions
Interactions
Cablivi Adverse Reactions
Adverse Reactions
Cablivi Clinical Trials
Cablivi Note
Not Applicable
Cablivi Patient Counseling
Cost Savings Program
The Cablivi savings program is available here.